Raymond T Chung MD
Hepatology & Liver Transplantation
Professor of Medicine, Harvard Medical School, Director of Hepatology and Liver Center, Massachusetts General Hospital
Join to View Full Profile
55 Fruit Street Blk 4Gastroenterology AssociatesBoston, MA 02114
Phone+1 617-724-6006
Fax+1 617-724-6832
Dr. Chung is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Raymond Chung is a gastroenterologist and hepatologist in Boston, MA and is Chief of Hepatology at Massachusetts General Hospital. He received his medical degree from Yale School of Medicine and has been in practice 31 years. He specializes in hepatology & liver transplantation and is experienced in hepatology.
Education & Training
Mass General Brigham/Massachusetts General HospitalFellowship, Gastroenterology, 1989 - 1993
Johns Hopkins UniversityResidency, Internal Medicine, 1986 - 1989
Yale School of MedicineClass of 1986
Certifications & Licensure
MA State Medical License 1989 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Gastroenterology
- American Board of Internal Medicine Transplant Hepatology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification Longitudinal Medical Record, Partners Healthcare System, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2013-2014, 2016-2017
Clinical Trials
- A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV) Start of enrollment: 2000 Nov 01
- Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV) Start of enrollment: 2004 Jul 01
- Assessment of the Antiviral Effect of Atorvastatin on Hepatitis C Virus Start of enrollment: 2006 Feb 01
Publications & Presentations
PubMed
- 3 citationsBile salt hydrolase activity as a rational target for MASLD therapy.Elizabeth V Jones, Yongtao Wang, Wenchao Wei, James C Reed, Snehal N Chaudhari
Gut Microbes. 2026-12-31 - Association between statin use and hepatic decompensation in patients with primary biliary cholangitis: A target trial emulation study.Jonggi Choi, Junqing Xu, Vy H Nguyen, Eric Przybyszewski, Daniel S Pratt
Hepatology. 2026-02-02 - 1 citationsLoss of Mtarc1 Protects Against Steatotic Liver Disease in Mice.Xiaofei Yin, Caroline Bickerton, Bryan MacDonald, Alessandro Arduini, Yunlong Shi
Liver International. 2026-02-01
Journal Articles
- Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Co-Infected with Human Immunodeficiency Virus (HIV): Results of the HBV-HIV Cohort StudyMandana Khalili, Mark Sulkowski, Marc G Ghany, Richard K Sterling, Raymond T Chung, David E Kleiner, Mamta K Jain, Nature
- A Novel lncRNA Regulates HCV Infection Through IFI6Raymond T Chung, Esperance A Schaefer, Hepatology
- Serum Angiopoietin‐2 Predicts Mortality and Kidney Outcomes in Decompensated CirrhosisAndrew S Allegretti, Sagar U Nigwekar, Raymond T Chung, Sahir Kalim, Xavier Vela Parada, Ravi I Thadhani, Guillermo A Ortiz, Samir M Parikh, Hepatology
Other
- Investigational therapies for hepatitis C virus infectionChung RT, Tai AW
http://www.uptodate.com/contents/investigational-therapies-for-hepatitis-c-virus-infection
UpToDate, Wolters Kluwer Health - 2013-04-05 - Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1Chung RT, Tai AW
http://www.uptodate.com/contents/studies-of-telaprevir-and-boceprevir-in-the-treatment-of-chronic-he
UpToDate, Wolters Kluwer Health - 2012-10-05
Authored Content
- The Nonalcoholic Fatty Liver Disease (NAFLD) Fibrosis Score, Cardiovascular Risk Stratification and a Strategy for Secondary Prevention with EzetimibeMay 2018
Press Mentions
Statin Use Linked to Lower Risk for Liver Cancer and DecompensationAugust 18th, 2025- Could Statins Prevent Hepatocellular Carcinoma?April 1st, 2025
- Statin Use Linked with Reduced Risks in Chronic Liver DiseaseMarch 17th, 2025
Grant Support
- Discovery And Assessment Of Genetic Determinants Of HCV And HIV ControlNational Institute On Drug Abuse2011
- Research Training In Digestive DiseasesNational Institute Of Diabetes And Digestive And Kidney Diseases2010–2011
- The Central Role Of The Hepatocyte In HCV PersistenceNational Institute Of Allergy And Infectious Diseases2009–2011
- Pilot/Feasibility Studies Program Of The HCV Persistence Study Group (HPSG)National Institute Of Allergy And Infectious Diseases2009–2011
- Mechanisms Of Immune Failure In Chronic Infection: Hepatitis C As A Key ParadigmNational Institute Of Allergy And Infectious Diseases2009–2011
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
